HomeBUSINESS
BUSINESS

Tolvaptan Re-Submitted to US FDA for ADPKD: Otsuka
(Nov.8.2017)

Otsuka Pharmaceutical said on November 5 that its vasopressin V2 receptor antagonist tolvaptan was re-submitted to the US FDA for the treatment of autosomal dominant polycystic kidney disease (ADPKD) four years after the regulator rejected the drug, requesting additional data ...
(LOG IN FOR FULL STORY)

News Calendar